Welcome to the April 2010 edition of the ISPOR eBulletin. The ISPOR eBULLETIN provides updates of
recent ISPOR activities and events. For detailed information on ISPOR
activities, members are encouraged to go to: www.ispor.org.
2010 ISPOR Board of Directors Election-LAST CHANCE TO VOTE
This is a final reminder to vote for the 2010-2011 ISPOR Board of Directors candidates. In this election, you have the opportunity to vote for the President-Elect (term of office 2010-2011 and as President 2011-2012) and four Directors (2010-2012). Please vote online via the ISPOR website.
ISPOR Board of Directors Election 2010 »
*Deadline to vote is: April 6, 2010.
2010 ISPOR Scientific Achievement Awards
The 2010 ISPOR Scientific Achievement Award recipients have been announced and will be presented at the ISPOR 15th Annual International Meeting.
ISPOR Scientific Achievement Awards »
ISPOR 15th Annual International Meeting
Atlanta, GA, USA
EARLY REGISTRATION DEADLINE: APRIL 6
Join the ISPOR 15th Anniversary celebrations!
For more information, go to:
ISPOR 15th Annual International Meeting »
ISPOR 4th Asia-Pacific Conference, Phuket, Thailand
38% INCREASE IN ABSTRACTS SUBMITTED!
For more information, go to:
ISPOR 4th Asia-Pacific Conference »
ISPOR 13th Annual European Congress
Prague, Czech Republic
Online abstract submission now open!
For more information, go to:
ISPOR 13th Annual European Congress »
Value in Health Early View Articles
37 Early View articles are available on-line, including 23 new articles added in the last month.
Value in Health Early View articles »
ISPOR Puerto Rico Regional Chapter
ISPOR welcomes the ISPOR Puerto Rico Regional Chapter. To learn more about this growing chapter as it promotes the implementation of pharmacoeconomic principles in the region, see:
ISPOR Puerto Rico Regional Chapter »
ISPOR Upstate NY Regional Chapter
ISPOR welcomes the ISPOR Upstate NY Regional Chapter. With over 20 members and ambitious objectives, the Chapter has a robust program planned for 2010. For more information or to JOIN the Chapter, see:
ISPOR Upstate NY Regional Chapter »
ISPOR Taiwan Regional Chapter Hosts the 2nd Forum of Asia Huaxia Pharmacoeconomics and Health Technology Assessment
The ISPOR Taiwan Chapter will host the 2nd Forum of Asia Huaxia Pharmacoeconomics and Health Technology Assessment at the School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, 3-4 April 2010.
ISPOR Asia Consortium »
ISPOR Venezuela Regional Chapter Monthly Bulletin
The ISPOR Venezuela Regional Chapter proudly announces the launching of a monthly bulletin in the Spanish language that will be a regular feature on the ISPOR Venezuela Regional Chapter webpage. Boletín ISPOR-Venezuela is an additional source to keep you up to date on the Chapter’s activities within Venezuela.
ISPOR Venezuela Regional Chapter »
ISPOR Health Technology Assessment (HTA) SIG
The HTA SIG group is continuously seeking new countries to add to the ISPOR Global Health Care Systems Road Map. The Road Map provides an overview of country-specific health care systems focusing on reimbursement systems, describes key decision-making players and decision-making processes for coverage and pricing. For more information, please see:
ISPOR Global Health Care Systems Road Map »
ISPOR Modeling Good Research Practices Task Force
This ISPOR Modeling Good Research Practices Task Force will build on the excellent work of the first ISPOR Task Force on Modeling in 2000-2003 and provide a guidance for: a) delineating the approach, design, and assessment of data for a modeling study; b) selecting a modeling technique; c) implementing and validating the model; d) addressing uncertainty around model results; e) reporting the modeling study results to assure transparency; and f) using model-based study results to inform decision-making. It is envisioned that this Task Force Report will consist of seven papers. For more information on this Task Force and specific topics to be address see:
ISPOR Modeling Good Research Practices Task Force »
The Risk Benefit Management Special Interest Group
The newly formed Risk Management and Ethics Working Group will be addressing ethical issues surrounding therapies developed from advanced scientific techniques. This new working group is looking for additional members to serve on either the leadership or reviewer group. For more information on the Risk Benefit Management SIG or for instructions how to become a member, see:
ISPOR Risk Benefit Management Special Interest Group »
To view ISPOR's Health Science Initiatives, Patient Reported Outcomes, and QOL Activities & Accomplishments from 1999 – 2006, go to the "Research" Tab on the purple tool bar and select any of our four areas.
August 16-18, 2010
Harvard School of Public Health, Boston, MA
Learn research in the newly funded area of comparative effectiveness studies.
Register Today! Visit: www.hsph.harvard.edu/ccpe/MDA or call: 617-384-8692
Improving your analytical and quantitative understanding and skills can greatly enhance the quality of health outcomes research at your organization.
In an increasingly competitive health care market, health outcomes research and evaluation is important for:
Improving patient outcomes including patient satisfaction●Controlling costs and allocating resources●Implementing disease management programs●Making effective clinical and business decisions●Developing and marketing health care products and services●Saving money by discouraging the use of costly, ineffective treatments
Group Discounts Available: Receive a 15% discount on each full tuition when three employees from the same organization register for a program. Receive a 20% discount when four or more colleagues register. That means, when you participate with four colleagues, a fifth colleague can attend tuition free! Let this excellent professional development opportunity serve as a team building experience for you and your colleagues. Please email us at: email@example.com or call us at 617.384.8692 for more information.
What Participants Are Saying (95% of participants rated the overall program as meeting or exceeding their expectations):
"The program and faculty exceeded my expectations. After participating in this program, I anticipate a 20% increase in the efficiency of my work in designing clinical trials." — Adina Soaita MD, DrPH, Clinical Statistician, Pfizer Inc., New London, CT
"Without hesitation I would recommend this program to any professional who is interested in health outcomes research." — Andrew J. Weis PharmD, Director, Outcomes Research, Pfizer Inc., Dallas, TX
CME and CEU Credits Available.
For a detailed agenda or to register, visit: www.hsph.harvard.edu/ccpe/MDA or call 617-384-8692. Please be sure to mention your Reference Code: MDA10-IP02 in all correspondence.
This program is recognized by the Society for Risk Analysis.
Career Opportunity in Patient Reported Outcomes
For more than 30 years, Genentech, now a member of the Roche group, has been at the forefront of the biotechnology industry, using human genetic information to develop novel medicines for serious and life-threatening diseases.
The Global Development Division is seeking a Principal Patient Reported Outcomes. This position will maximize the value of multiple agents within a therapeutic area by leading and developing Patient Reported Outcome (PRO) strategies for molecules during early clinical development. The successful candidate will:
- Work cross-functionally with several departments to develop PRO strategies
- Ensure relevant PRO endpoints and study design for registration clinical trial programs meet the needs of global regulatory agencies and key stakeholders
- Identify PRO instruments and evaluate measurement and psychometric properties of the instruments
- Work with external key opinion leaders and regulatory agencies to obtain guidance on PRO strategies
- Contribute to the design, implementation, and management of registration clinical trials containing PROs including the development of the PRO sections of study concept documents, study protocols, statistical analysis plans, clinical study reports and other development documents
- Develop and/or validate instruments for PRO as needed
- Adapt and validate instruments for use in different patient populations, including cultural adaptations and translations
- Work with Global Scientific Communications to develop publication plan that is integrated with overall publication strategy to communicate PRO information to physicians, patients, payers and policy makers
- Manage vendors including scope of work development, contract initiation and project milestones, timelines, deliverables and budgets
Depending on the preference of the candidate, the position will be located in South San Francisco, California, Nutley, New Jersey, Welwyn, England or Basel, Switzerland.
An advanced degree in Psychology, Epidemiology, Health Services Research, Outcomes Research or a related discipline is preferred. A minimum of five years of professional experience in PRO assessment and/or psychometric validation is required. The candidate must have familiarity and experience with the development and implementation of research strategies (including PRO within registration clinical trials), as well as a strong understanding of research methodology and statistics.
To learn more about this opportunity, please contact Robin Shaw at: firstname.lastname@example.org or at 650-225-7918. Genentech is an equal opportunity employer.